Aptorum Group (NYSE: APM) — Perfil da empresa, notícias e dados financeiros
Aptorum Group develops innovative therapeutics and diagnostics to address unmet medical needs in various fields.
Aptorum Group
Aptorum Group (NASDAQ:APM) is a dynamic biopharmaceutical company dedicated to developing and commercializing a diverse range of innovative therapeutic and diagnostic technologies targeting unmet medical needs. With a strategic focus on infectious diseases and oncology, among other fields, Aptorum is actively engaged in advancing its pipeline through rigorous research and development efforts. They are committed to leveraging cutting-edge science and technology to provide new solutions that can significantly improve patient outcomes and quality of life. Their objective is to lead the way in discovering and developing novel therapeutics and diagnostics that address the critical challenges faced by patients around the globe.
Resumo
Operações
Produtos e/ou serviços de Aptorum Group
- Smart Pharma - Utilizes artificial intelligence for drug discovery and development processes.
- SACT-1 - A repurposed drug aimed at treating neuroblastoma.
- ALS-4 - An antimicrobial for Staphylococcus aureus infections, including MRSA.
equipe executiva do Aptorum Group
- Mr. Chung Yuen HuenFounder, CEO & Executive Director
- Mr. Kwok Kuen WongHead of Finance
Principais indicadores financeiros
Resultados divulgados pela Aptorum Group , em USD.
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -1,8 mi | -1,4 mi | |
| 0 | -3,8 mi | -4,3 mi | |
| 431,4 mil | -10,6 mi | -2,8 mi | |
| 1,3 mi | -17,5 mi | -9,8 mi |